<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-614" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Stentless Autograft/Homograft Aortic Valve Replacement</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ali</surname>
            <given-names>Muhammad Ashar</given-names>
          </name>
          <aff>Saint Clare's Denville Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Sanjeev</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chowdhury</surname>
            <given-names>Yuvraj S.</given-names>
          </name>
          <aff>State University of New York - Downstate</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Ashar Ali declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sanjeev Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yuvraj Chowdhury declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-614.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Stentless auto- and homograft aortic valve replacements are advanced surgical techniques that address severe aortic valve disease, including aortic stenosis and regurgitation. One such technique, the Ross procedure, uses the patient's pulmonary valve as an autograft; this offers benefits such as better long-term durability and a reduced risk of endocarditis compared to mechanical valves. Homografts, derived from human donors, provide a viable alternative with favorable outcomes&#x02014;especially when decellularized&#x02014;as they minimize immunogenicity and improve longevity. Both techniques are particularly advantageous for younger patients and those with future pregnancy plans; however, these techniques come with specific risks and considerations, including the potential need for reintervention.</p>
        <p>Clinicians participating in this activity gain a comprehensive understanding of the indications, techniques, and outcomes associated with stentless auto- and homograft aortic valve replacements. The course enhances clinicians' ability to evaluate patient suitability for these procedures and provides a better understanding of the nuances of surgical techniques to help effectively manage postoperative care. By collaborating with an interprofessional team, including cardiologists, surgeons, anesthesiologists, and nurses, healthcare professionals improve their decision-making and patient care strategies.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate patient population for stentless autograft or homograft aortic valve replacement based on clinical indications and individual patient factors.</p></list-item><list-item><p>Differentiate between stentless autograft and homograft options, understanding their specific benefits, limitations, and indications for use in aortic valve replacement.</p></list-item><list-item><p>Apply evidence-based guidelines and recent research findings to inform decision-making and improve patient outcomes in stentless autograft and homograft aortic valve replacement.</p></list-item><list-item><p>Collaborate with multidisciplinary teams to manage complex cases, ensure comprehensive patient care, and address any issues related to stentless autograft and homograft aortic valve replacement.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=614&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=614">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-614.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>A valve is a mobile, thin sheet of tissue that ensures unidirectional flow through a passage. In the heart, valves can become insufficient or stenosed, leading to various health conditions. Valvular heart disease is a significant public health issue, affecting approximately 2.5% of the population. Among the various types of valvular heart disease, aortic valve disease, including aortic stenosis and regurgitation, is particularly prevalent. Damaged aortic valves are managed through medications, aortic valve repair, or surgical or transcatheter aortic valve replacement.<xref ref-type="bibr" rid="article-614.r1">[1]</xref><xref ref-type="bibr" rid="article-614.r2">[2]</xref>&#x000a0;Selecting an appropriate valve replacement strategy is crucial and depends on multiple factors, such as patient preference, age, anticoagulation tolerance, risk of valve deterioration, anticoagulation status, and future pregnancy plans.</p>
        <p>Prosthetic heart valves used for aortic valve replacement are either mechanical or bioprosthetic. Mechanical heart valves include disc, bileaflet, and ball-and-cage types; bioprosthetic valves are categorized into xenografts (from animals), homografts (from the same species), and autografts (from the same individual). Bioprosthetic valves may be stented on metallic support or directly attached to the aorta.<xref ref-type="bibr" rid="article-614.r3">[3]</xref> Stentless auto- and homograft aortic valve replacements have emerged as important surgical options for patients requiring valve replacement, offering distinct benefits compared to traditional stented prosthetic valves.</p>
        <p>Although stent placement can reduce the aortic valve lumen and is not hemodynamically favorable, it does not significantly impact the clinical outcomes of stentless autograft and homograft valve types.<xref ref-type="bibr" rid="article-614.r4">[4]</xref> This finding underscores the importance of considering hemodynamic performance and other patient-specific factors when selecting a valve replacement strategy. Moreover, different types of bioprosthetic valves exhibit similar mortality and reoperation rates, further highlighting the need for individualized patient care.<xref ref-type="bibr" rid="article-614.r5">[5]</xref>&#x000a0;Transcatheter aortic valve replacement offers a safer alternative for patients who aren't candidates for open-heart valve replacement surgery. However, stentless autograft and homograft aortic valve replacements remain valuable options for many patients, especially younger individuals and those with specific clinical indications.</p>
      </sec>
      <sec id="article-614.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>
<bold>Aortic Valve</bold>
</p>
        <p>The aortic valve is&#x000a0;1 of the&#x000a0;4 valves of the heart, located between the left ventricle (LV) and the ascending aorta.&#x000a0;This tricuspid valve has&#x000a0;3 cusps or leaflets&#x000a0;of different sizes&#x02014;right, left, and noncoronary.<xref ref-type="bibr" rid="article-614.r6">[6]</xref>&#x000a0;The noncoronary cusp can range from 14 to 28 mm, while the left and right coronary cusps can range from 12 to 25 mm. Results from one study found a mean geometric height of 19 mm for the tricuspid aortic valve.<xref ref-type="bibr" rid="article-614.r7">[7]</xref>&#x000a0;These leaflets are thin, flexible, and attached to the aortic annulus, a fibrous ring that provides structural support. When the LV contracts, the aortic valve opens to allow blood to flow from the heart into the aorta and then to the rest of the body. During diastole, when the&#x000a0;LV relaxes, the aortic valve closes to prevent the backflow of blood into the ventricle.</p>
        <p>
<bold>Aortic Regurgitation</bold>
</p>
        <p>Aortic regurgitation (AR) is the backflow of blood from the aorta into the&#x000a0;LV during diastole due to inadequate aortic valve closure. Causes include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Valve leaflet abnormalities: Abnormalities include a congenital bicuspid valve (eg, having 2&#x000a0;leaflets instead of&#x000a0;3), degenerative changes, or endocarditis.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Aortic root dilation: Conditions like Marfan syndrome, aortic dissection, or hypertension can cause dilation of the aortic root, pulling the leaflets apart and preventing proper closure.</p>
          </list-item>
        </list>
        <p>Regurgitant flow increases the volume load on the LV, causing it to dilate and eventually hypertrophy. This volume overload leads to elevated left ventricular end-diastolic pressure, decreased cardiac output, and progressive&#x000a0;LV dysfunction.&#x000a0;AR leads to a diastolic blowing-type murmur in the third intercostal space on the left side along the sternal border. Patients with&#x000a0;AR may experience symptoms such as palpitations, fatigue, dyspnea, and, in severe cases, heart failure.<xref ref-type="bibr" rid="article-614.r8">[8]</xref></p>
        <p>The American College of Cardiology/American Heart Association (ACC/AHA) provide guidelines that categorize AR into&#x000a0;4 stages: A, B, C, and D, based on valve anatomy, valve hemodynamics,&#x000a0;LV response, and symptoms. The stages are:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage A: At risk for AR</bold>
<list list-type="bullet"><list-item><p>Patients with conditions that predispose them to AR, such as bicuspid aortic valve, aortic dilatation, or history of endocarditis</p></list-item><list-item><p>No significant valve dysfunction or regurgitation</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Stage B: Progressive&#x000a0;AR</bold>
<list list-type="bullet"><list-item><p>Mild to moderate AR</p></list-item><list-item><p>Normal LV&#x000a0;size, function&#x000a0;</p></list-item><list-item><p>Asymptomatic or mild symptoms</p></list-item><list-item><p>Echocardiographic findings:
<list list-type="bullet"><list-item><p>Effective regurgitant orifice area (EROA) &#x0003c;0.10 cm&#x000b2;</p></list-item><list-item><p>Regurgitant volume &#x0003c;30 mL/beat</p></list-item><list-item><p>Regurgitant fraction &#x0003c;30%</p></list-item><list-item><p>Left ventricular end-diastolic dimension typically &#x0003c;60 mm</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Stage C: Asymptomatic severe&#x000a0;AR</bold>
<list list-type="bullet"><list-item><p><bold>C1: Asymptomatic severe&#x000a0;AR with normal LV function</bold>
<list list-type="bullet"><list-item><p>Severe AR without symptoms</p></list-item><list-item><p>Normal left ventricular ejection fraction (LVEF) &#x02265;50%</p></list-item><list-item><p>Echocardiographic findings:
<list list-type="bullet"><list-item><p>EROA &#x02265;0.30 cm&#x000b2;</p></list-item><list-item><p>Regurgitant volume &#x02265;60 mL/beat</p></list-item><list-item><p>Regurgitant fraction &#x02265;50%</p></list-item><list-item><p>Left ventricular end-diastolic diameter (LVEDD) &#x02265;60 mm, but LVEF &#x02265;50%</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p><bold>C2: Asymptomatic severe&#x000a0;AR with LV dysfunction</bold>
<list list-type="bullet"><list-item><p>Severe AR without symptoms</p></list-item><list-item><p>LV dysfunction (LVEF &#x0003c;50%)</p></list-item><list-item><p>Echocardiographic findings:
<list list-type="bullet"><list-item><p>The same criteria for AR severity as C1</p></list-item><list-item><p>LVEDD &#x02265;70 mm or LVEF &#x0003c;50%</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Stage D: Symptomatic severe&#x000a0;AR</bold>
<list list-type="bullet"><list-item><p><bold>D1: Symptomatic severe&#x000a0;AR with normal LV function</bold>
<list list-type="bullet"><list-item><p>Severe AR with symptoms such as dyspnea, fatigue, or palpitations</p></list-item><list-item><p>Normal&#x000a0;LV function (LVEF &#x02265;50%)</p></list-item><list-item><p>Echocardiographic findings:
<list list-type="bullet"><list-item><p>EROA &#x02265;0.30 cm&#x000b2;</p></list-item><list-item><p>Regurgitant volume &#x02265;60 mL/beat</p></list-item><list-item><p>Regurgitant fraction &#x02265;50%</p></list-item><list-item><p>LVEDD &#x02265;60 mm, but LVEF &#x02265;50%</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p><bold>D2: Symptomatic severe AR&#x000a0;with LV dysfunction</bold>
<list list-type="bullet"><list-item><p>Severe AR with symptoms</p></list-item><list-item><p>LV dysfunction (LVEF &#x0003c;50%)</p></list-item><list-item><p>Echocardiographic findings:
<list list-type="bullet"><list-item><p>The same criteria for AR severity as D1</p></list-item><list-item><p>LVEDD &#x02265;70 mm or LVEF &#x0003c;50%</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Aortic Stenosis</bold>
</p>
        <p>Aortic stenosis (AS) is characterized by narrowing of&#x000a0;the aortic valve opening, which restricts blood flow from the&#x000a0;LV into the aorta. This condition can be caused by several factors, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Congenital defects
<list list-type="bullet"><list-item><p>Bicuspid aortic valve</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Calcific degeneration
<list list-type="bullet"><list-item><p>Age-related calcification and hardening of the valve leaflets</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Rheumatic fever
<list list-type="bullet"><list-item><p>An inflammatory disease that can cause scarring and fusion of the valve leaflets</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>The narrowed valve increases resistance to blood flow, leading to higher pressure within the LV. To overcome this resistance, the&#x000a0;LV compensates by hypertrophying. Over time, this increased workload can lead to&#x000a0;LV dysfunction, heart failure, and symptoms such as angina, syncope, fatigue, and dyspnea.&#x000a0;AS leads to a crescendo-decrescendo systolic murmur in the right-second intercostal space that radiates to the carotids.</p>
        <p>The diagnosis of&#x000a0;AS typically begins with a physical examination and is confirmed through echocardiography (ECG). &#x000a0;Findings on ECG, such as&#x000a0;LV hypertrophy with strain and left atrial enlargement, are nonspecific.&#x000a0;Two-dimensional ECG can reveal a thickened aortic valve, reduced leaflet mobility, and concentric&#x000a0;LV hypertrophy. An ECG can also quantify the severity of AS, assess the&#x000a0;LV size and the presence of concurrent aortic or mitral regurgitation, and estimate pulmonary systolic pressure.&#x000a0;Chest radiography may show a normal cardiac size due to concentric hypertrophy in AS, but cardiomegaly may appear once LV systolic failure occurs. Calcification of the aortic valve, pulmonary congestion, and poststenotic dilation of the aorta are other nonspecific findings. Cardiac catheterization is indicated to evaluate coexistent coronary disease or when aortic valve replacement is indicated.&#x000a0;</p>
        <p>The 2020 ACC/AHA guidelines categorize&#x000a0;AS into&#x000a0;4 stages defined by valve anatomy, hemodynamics, changes in the&#x000a0;LV and vasculature, and the presence or absence of symptoms. The key hemodynamic parameters for staging include the maximum transaortic velocity (Vmax), mean pressure gradient (&#x00394;P) across the aortic valve, and aortic valve area (AVA).&#x000a0;The transvalvular pressure gradient and cardiac output are determined at catheterization, and the AVA is calculated using the Gorlin equation. The stages are as follows:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage A: At risk for AS</bold>
<list list-type="bullet"><list-item><p>Characterized by aortic valve sclerosis or a congenital anomaly</p></list-item><list-item><p>Vmax &#x0003c;2 m/s</p></list-item><list-item><p>No hemodynamic consequences</p></list-item><list-item><p>No symptoms</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Stage B: Progressive hemodynamic obstruction</bold>
<list list-type="bullet"><list-item><p>Involves mild to moderate calcification/fibrosis</p></list-item><list-item><p>Mild (Vmax 2.0&#x02013;2.9 m/s, &#x00394;P &#x0003c;20 mm Hg) to moderate AS (Vmax 3.0&#x02013;3.9 m/s, &#x00394;P 20&#x02013;39 mm Hg)</p></list-item><list-item><p>Normal LVEF, early diastolic dysfunction</p></list-item><list-item><p>No symptoms</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Stage C: Asymptomatic severe AS</bold>
<list list-type="bullet"><list-item><p>Severe leaflet calcification/fibrosis or congenital stenosis of the aortic valve, with strongly reduced leaflet motion
<list list-type="bullet"><list-item><p><bold>C1: Asymptomatic severe AS with normal LV function</bold>
<list list-type="bullet"><list-item><p>Severe AS without symptoms</p></list-item><list-item><p>LVEF &#x02265;50%</p></list-item><list-item><p>Vmax &#x02265;4 m/s or mean &#x00394;P &#x02265;40 mm Hg</p></list-item></list>
</p></list-item><list-item><p><bold>C2: Asymptomatic severe AS with LV systolic dysfunction</bold>
<list list-type="bullet"><list-item><p>LVEF &#x0003c;50%</p></list-item><list-item><p>Vmax &#x02265;4 m/s or &#x00394;P &#x02265;40 mm Hg</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Stage D: Symptomatic Severe AS</bold>
<list list-type="bullet"><list-item><p>Severe leaflet calcification/fibrosis or congenital stenosis, which&#x000a0;significantly restricts leaf motion/opening
<list list-type="bullet"><list-item><p><bold>D1: Symptomatic severe high-gradient AS</bold>
<list list-type="bullet"><list-item><p>Vmax &#x02265;4 m/s or mean &#x00394;P &#x02265;40 mm Hg</p></list-item><list-item><p>AVA is typically&#x000a0;&#x02264;1.0 cm<sup>2</sup></p></list-item><list-item><p>LV hypertrophy and diastolic dysfunction are present</p></list-item><list-item><p>May also be pulmonary hypertension</p></list-item><list-item><p>Symptoms: exertional dyspnea, decreased exercise tolerance or heart failure, exertional angina, and exertional syncope or presyncope</p></list-item></list>
</p></list-item><list-item><p><bold>D2</bold>:&#x000a0;<bold>Symptomatic severe low-flow, low-gradient AS with reduced LVEF</bold>
<list list-type="bullet"><list-item><p>Resting aortic Vmax &#x0003c;4 m/s or mean &#x00394;P &#x0003c;40 mm Hg and an AVA &#x02264;1.0 cm<sup>2</sup></p></list-item><list-item><p>LV hypertrophy and diastolic dysfunction are present</p></list-item><list-item><p>LVEF &#x0003c;50%</p></list-item><list-item><p>Symptoms: heart failure, angina, and syncope or presyncope.</p></list-item></list>
</p></list-item><list-item><p><bold>D3</bold>:&#x000a0;<bold>Symptomatic severe low-gradient AS with normal LVEF</bold>
<list list-type="bullet"><list-item><p>Resting aortic Vmax &#x0003c;4 m/s or mean &#x00394;P &#x0003c;40 mm Hg and an AVA &#x02264;1.0 cm<sup>2</sup></p></list-item><list-item><p>LVEF &#x02265;50%</p></list-item><list-item><p>Stroke volume index &#x0003c;35 mL/m<sup>2</sup></p></list-item><list-item><p>Symptoms: heart failure, angina, and syncope or presyncope</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Notably, any damage to the heart valves, including AR and AS, puts patients at risk for endocarditis. Characteristic features of endocarditis are fever, pulmonary infarcts, arterial emboli, Janeway lesions, splinter hemorrhages, conjunctival hemorrhages, painful Osler nodes, Roth spots, glomerulonephritis, new-onset heart murmur, and positive blood cultures. Duke criteria are used to assess the probability of endocarditis.<xref ref-type="bibr" rid="article-614.r9">[9]</xref></p>
      </sec>
      <sec id="article-614.s4" sec-type="Indications">
        <title>Indications</title>
        <p>The indications for stentless autograft/homograft aortic valve replacement include the following:</p>
        <p>
<bold>
<bold>Aortic Regurgitation</bold>
</bold>
</p>
        <p>AR&#x000a0;is initially&#x000a0;treated&#x000a0;with diuretics and vasodilators for symptomatic management. The following are indications for&#x000a0;aortic valve replacement in patients with AR:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage D AR</p>
          </list-item>
          <list-item>
            <p>Stage C2&#x000a0;AR&#x000a0;with&#x000a0;LVEF &#x0003c;50%,&#x000a0;left ventricular end-systolic dimension &#x0003e;50 mm, or&#x000a0;LVEDD &#x0003e;65 mm</p>
          </list-item>
          <list-item>
            <p>Stage B, C, or D AR undergoing any other cardiac surgery&#x000a0;<xref ref-type="bibr" rid="article-614.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>Current data are insufficient to indicate a specific type of prosthesis for aortic valve replacement. However, the following points favor a bioprosthetic heart valve:</p>
        <list list-type="bullet">
          <list-item>
            <p>Contraindications, noncompliance, or refractory to anticoagulant drugs</p>
          </list-item>
          <list-item>
            <p>Fully informed patients' desire</p>
          </list-item>
          <list-item>
            <p>Patients with mechanical valve thrombosis</p>
          </list-item>
          <list-item>
            <p>Low risk of valve redo operations</p>
          </list-item>
          <list-item>
            <p>Future pregnancy plans</p>
          </list-item>
          <list-item>
            <p>Being 65 or older&#x000a0;<xref ref-type="bibr" rid="article-614.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>
<bold>Aortic Stenosis</bold>
</bold>
</p>
        <p>AS&#x000a0;is initially managed symptomatically with beta-blockers (eg, atenolol, carvedilol, metoprolol), calcium channel blockers (eg, verapamil, diltiazem), diuretics (eg, furosemide, thiazides), or angiotensin-converting enzyme (ACE) inhibitors. The following are commonly used indications for aortic valve replacement in patients with AS:</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage D1&#x000a0;AS</p>
          </list-item>
          <list-item>
            <p>Stage C2&#x000a0;AS; LVEF &#x0003c;50%</p>
          </list-item>
          <list-item>
            <p>Stage C1 AS; low exercise tolerance</p>
          </list-item>
          <list-item>
            <p>Stage C1 AS; Vmax &#x02265;4.5 m/s with low surgical risk</p>
          </list-item>
          <list-item>
            <p>Stage C or D&#x000a0;AS undergoing any other cardiac surgery&#x000a0;<xref ref-type="bibr" rid="article-614.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Graft Choice</bold>
</p>
        <p>Autograft aortic valve replacement is performed using the Ross procedure, which is particularly favored for children and young adults (see&#x000a0;<bold>Image.&#x000a0;</bold>Ross Procedure). This technique uses the patient's pulmonary valve to replace the defective aortic valve, which is subsequently replaced by a bovine jugular vein conduit in patients younger than 6&#x000a0;or in older patients with a decellularized pulmonary homograft.<xref ref-type="bibr" rid="article-614.r12">[12]</xref><xref ref-type="bibr" rid="article-614.r13">[13]</xref> This approach leverages the potential of the pulmonic valve to grow and regenerate, along with a lower risk of endocarditis.<xref ref-type="bibr" rid="article-614.r12">[12]</xref>&#x000a0;</p>
        <p>Homografts, sourced from cadaveric or brain-dead heart donors, are preferred in cases of aortic valve endocarditis, especially with periannular abscesses, as the periannular graft tissue can patch these defects. They are also recommended for patients with a history of intravenous drug use with endocarditis due to their higher risk of reoperations.<xref ref-type="bibr" rid="article-614.r14">[14]</xref>&#x000a0;Xenografts, on the other hand, are readily available in all sizes.<xref ref-type="bibr" rid="article-614.r15">[15]</xref></p>
      </sec>
      <sec id="article-614.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Common contraindications for the Ross procedure include connective tissue diseases (eg, Marfan and Ehlers-Danlos syndrome) and inflammatory conditions like rheumatoid arthritis and systemic lupus erythematosus. These conditions often involve the pulmonary aorta or pulmonary valve, making them unsuitable candidates for this procedure. Additional contraindications include multiple vessel coronary artery disease, severely decreased&#x000a0;LV function or any existing pulmonary valve pathology. There are no specific contraindications for aortic valve homografts other than the availability of the donor and the preference of the surgeon and patient. However, young age is considered a relative contraindication for homograft valve replacement due to the potential for future growth and the need for reoperation.<xref ref-type="bibr" rid="article-614.r15">[15]</xref><xref ref-type="bibr" rid="article-614.r16">[16]</xref></p>
      </sec>
      <sec id="article-614.s6" sec-type="Equipment">
        <title>Equipment</title>
        <p>Aortic heart valve replacement, including the Ross procedure, is performed via open median sternotomy. The heart valves are initially assessed with echocardiography. Essential equipment for the procedure includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hegar dilator is used to measure the autografts.</p>
          </list-item>
          <list-item>
            <p>Polypropylene sutures are used to attach the graft valve securely.</p>
          </list-item>
          <list-item>
            <p>Dacron tube is employed to extend the pulmonary valve.<xref ref-type="bibr" rid="article-614.r17">[17]</xref><xref ref-type="bibr" rid="article-614.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Cardiopulmonary bypass machine is essential for maintaining circulation and oxygenation during the surgery.</p>
          </list-item>
          <list-item>
            <p>Aortic cross-clamp is used to&#x000a0;isolate the aorta and control blood flow.</p>
          </list-item>
          <list-item>
            <p>Surgical instruments are standard instruments such as scalpels, scissors, forceps, and needle holders.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-614.s7" sec-type="Personnel">
        <title>Personnel</title>
        <p>A team consisting of an anesthesiologist, cardiac surgeon, cardiologist, surgery assistant, operation room assistant, radiologist, nurses, and additional staff members is&#x000a0;required to perform an aortic heart valve replacement surgery.<xref ref-type="bibr" rid="article-614.r19">[19]</xref></p>
      </sec>
      <sec id="article-614.s8" sec-type="Preparation">
        <title>Preparation</title>
        <p>The main goal of preparation is sterility. Before starting the procedure, the chest is shaved and sterilized. The patient is draped based on the institution's protocols, and other general anesthesia-related preparations are done. Important landmarks (eg, jugulum and xiphoid process) are identified and marked before starting the procedure.<xref ref-type="bibr" rid="article-614.r19">[19]</xref><xref ref-type="bibr" rid="article-614.r20">[20]</xref></p>
      </sec>
      <sec id="article-614.s9" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>Aortic valve replacement via the Ross procedure is performed through a median sternotomy with bicaval and aortic cannulation. Cardioplegia is typically achieved with cold intermittent techniques, followed by warm reperfusion before releasing the aortic clamp. The common adventitia between the pulmonary root and aorta is dissected to access the muscular infundibulum. The aortic and pulmonary valves are inspected before extraction. The route of coronary arteries and their branches is carefully considered during these procedures.<xref ref-type="bibr" rid="article-614.r14">[14]</xref>&#x000a0;The pulmonary valve is carefully extracted, ensuring it remains intact and the first septal coronary artery is preserved. The Hegar dilator is used to measure the autograft.</p>
        <p>Next, the diseased aortic valve is removed, and the annulus is measured to ensure a match with the graft. Annuloplasty is performed if there is any mismatch. The valve leaflets are then attached to the aorta using polypropylene sutures. After the autograft implantation, the left coronary button is anastomosed first, followed by the others. The distal anastomosis of the pulmonary graft is performed first, followed by the distal anastomosis of the aortic graft. The final step is securing the proximal portion of the pulmonary graft with a running suture.<xref ref-type="bibr" rid="article-614.r18">[18]</xref><xref ref-type="bibr" rid="article-614.r21">[21]</xref></p>
        <p>Homograft aortic valve replacement is performed through a median sternotomy, followed by cardioplegia. During the procedure, the surgeon removes all infected tissue and the damaged aortic valve. This debridement process can sometimes create a defect at the mitroaortic junction. The anterior mitral leaflet or a part of a leaflet from the graft is used to fill the defect. The atrium is then sutured, and a pericardial patch is applied if needed.<xref ref-type="bibr" rid="article-614.r17">[17]</xref></p>
      </sec>
      <sec id="article-614.s10" sec-type="Complications">
        <title>Complications</title>
        <p>About 30% of patients experience pulmonary autograft dilatation after the Ross procedure. Patients younger than 25 almost always require autograft reintervention at some point in their lives.Younger age is also associated with right ventricular outflow tract conduit degeneration. Older patients face a 32% to 68% risk of reintervention due to graft valve-related complications. The Ross procedure has comparatively lower rates of bleeding, thrombosis, and endocarditis-related complications than other types of graft replacements and is associated with a smaller number of early and late mortalities.<xref ref-type="bibr" rid="article-614.r22">[22]</xref><xref ref-type="bibr" rid="article-614.r23">[23]</xref></p>
        <p>The Melbourne group has extensive experience with autologous support of the pulmonary autograft root using the patient's aorta, known as the inclusion technique. They reported long-term outcomes for this technique in 322 consecutive patients. Before implanting the pulmonary autograft, the native aorta and aortic root remnants were modified to achieve specific measurements for the sinotubular junction and aortic annulus: 24 to 26 mm for men and 22 to 24 mm for women. The long-term results are remarkable, showing stable neoaortic dimensions up to 15 years post-surgery. Only 1.5% of patients developed a maximum aortic root size exceeding 40 mm in diameter, with none surpassing 43 mm. Previous study results indicated that patients with preoperative AR and those with a large aortic annulus were at a higher risk for developing larger neoaortic root diameters during follow-up and were more likely to require reoperation. Despite these risks, the overall freedom from autograft reoperation at 18 years was 96%, with no reoperations due to autograft dilatation.<xref ref-type="bibr" rid="article-614.r24">[24]</xref></p>
        <p>Homograft aortic valve replacement may lead to early mortality, but the incidence is low. Due to the rupture of a graft leaflet, calcification of the graft valve, or poor coaptation of leaflets, structural deterioration of the graft may occur in about 20 years. Early results from the prospective Australasian Resuscitation In Sepsis Evaluation,<italic toggle="yes">&#x000a0;</italic>ARISE, trial and registry, which includes 223 patients, show outcomes similar to those in&#x000a0;another study. The ARISE trial reports outcomes after an average follow-up of 1.54 &#x000b1; 0.81 years for the prospective arm and 2.60 &#x000b1; 2.13 years for the registry cohort. In&#x000a0;the study's&#x000a0;analysis, 36% of the patients were also part of the early results of the prospective trial.</p>
        <p>Additionally, 38% of the registry cohort were pediatric patients, resulting in a lower mean age of 28.7 &#x000b1; 19.8 years compared to 47.0 &#x000b1; 11.4 years in&#x000a0;the study cohort. The authors of the ARISE trial reported very low rates of adverse events, similar to the study. Five years postprocedure, the reported rates of freedom from mortality, endocarditis, reoperations, bleeding, and thromboembolic events were 98.2 &#x000b1; 0.9%, 97.3 &#x000b1; 2.2%, 90.8 &#x000b1; 4.0%, 99.5 &#x000b1; 0.5%, and 99.5 &#x000b1; 0.5%, respectively.<xref ref-type="bibr" rid="article-614.r25">[25]</xref><xref ref-type="bibr" rid="article-614.r26">[26]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-614.s11" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Valvular heart disease poses a significant public health challenge, affecting approximately 2.5% of the population, with AS and AR constituting a considerable portion of valvular heart disease cases. The prevalence of&#x000a0;AS varies by region and notably increases with age, affecting 0.2% of individuals in their 50s and up to 9.8% of those 80 to 89. The most common congenital heart defect, the bicuspid aortic valve, has a prevalence of 0.5% to 0.8% and often necessitates surgical intervention in younger patients, typically around age 50. Additionally, significant&#x000a0;AR affects 0.5% of the population, with its frequency increasing&#x000a0;with age.<xref ref-type="bibr" rid="article-614.r27">[27]</xref></p>
        <p>Despite the Ross procedure being introduced over&#x000a0;5 decades ago, its application in adult clinical practice remains debated. However, substantial evidence highlights its benefits. The primary advantages include improved long-term survival, avoidance of anticoagulant therapy, a low incidence of endocarditis, and an infrequent need for reintervention. The living tissue of the autograft maintains native valve physiology and retains contractile and neurohumoral responsiveness, leading to superior hemodynamics and an enhanced quality of life. These characteristics make the Ross procedure ideal for pediatric and young patients, with pediatric cases showing lower mortality and a lower rate of reinterventions than other graft procedures.<xref ref-type="bibr" rid="article-614.r12">[12]</xref>&#x000a0;</p>
        <p>Homograft aortic valve replacement, while complex, yields favorable clinical outcomes, particularly in adults and patients planning future pregnancies.<xref ref-type="bibr" rid="article-614.r28">[28]</xref> Compared to cryopreserved nondecellularized homografts, decellularized homografts are anticipated to offer improved durability, especially given the limited longevity of cryopreserved grafts in younger patients. Study results have demonstrated that decellularized homografts exhibit significantly higher freedom from explantation and lower rates of structural valve degeneration&#x000a0;10 years post-intervention.<xref ref-type="bibr" rid="article-614.r29">[29]</xref> For instance, results from a 2016 study by Helder et al reported that 51% of 41 patients who received decellularized homografts between 2002 and 2004 were free from reoperation after&#x000a0;10 years. Despite differences in decellularization techniques and small sample sizes, extended follow-up studies are crucial for these grafts. An intrinsic benefit of decellularized homografts is their low immunogenicity, which is particularly important for patients who may require organ transplantation.<xref ref-type="bibr" rid="article-614.r27">[27]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-614.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Stentless autograft/homograft aortic valve replacement requires a high level of skill, strategy, and coordinated care from an interprofessional team to ensure optimal patient-centered care and outcomes. Physicians and surgeons must possess advanced surgical skills and a deep understanding of cardiovascular anatomy and pathology to successfully perform these complex procedures. Advanced clinicians and nurses are critical in perioperative care, including patient education, preoperative assessments, and postoperative monitoring. Their ability to identify complications early and provide timely interventions is crucial for patient safety. Pharmacists contribute by managing anticoagulation therapy, ensuring proper medication reconciliation, and providing guidance on postoperative medications to prevent infections and manage pain.</p>
        <p>Effective interprofessional communication is essential for enhancing team performance and patient outcomes. Regular interdisciplinary meetings and clear, concise handoffs ensure that all team members are informed about the patient's condition and care plan. Care coordination, including collaboration between cardiologists, cardiothoracic surgeons, anesthesiologists, and rehabilitation specialists, helps streamline the patient's journey from preoperative evaluation to postoperative recovery. This integrated approach not only enhances patient safety by reducing the risk of errors but also promotes a seamless transition of care&#x02014;ultimately improving the overall patient experience and outcomes. By fostering a culture of teamwork and continuous communication, healthcare professionals can deliver high-quality, patient-centered care in stentless autograft/homograft aortic valve replacement.</p>
      </sec>
      <sec id="article-614.s13" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>The aortic valve replacement procedure is major cardiac surgery. There should not be any communication gap between the team members. A thorough assessment of the patient before, during, and after the procedure leads to better outcomes. Negligence can lead to preventable adverse events. Appropriate care provides better results after heart valve replacement. Phase 2 randomized clinical trial results have shown better VO<sub>2</sub>&#x000a0;max (maximum oxygen utilized during exercise) in patients with cardiac rehabilitation.<xref ref-type="bibr" rid="article-614.r30">[30]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-614.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=614&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=614">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/614/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=614">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-614.s15">
        <fig id="article-614.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Recommendations for Aortic Valve Replacement Table. The recommendations, classes of recommendations, and level of evidence for aortic valve replacement are detailed in the table. Contributed by S Harika, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Aortic__Valve__Repair" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-614.s16">
        <fig id="article-614.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Indications for Aortic Valve Replacement. Contributed by S Harika Pujari, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Symptomatic" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-614.s17">
        <fig id="article-614.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Ross Procedure.&#x000a0;Technical modifications of the Ross procedure have been developed to prevent late autograft dilatation and insufficiency. These include: (A) Autologous inclusion technique; (B) Dacron inclusion technique; and(C) Tailored surgical approach. Contributed by I El-Hamamsy, MD&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screen__Shot__2024-07-05__at__10.00.58__AM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-614.s18">
        <title>References</title>
        <ref id="article-614.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Carabello</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Erwin</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Jneid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Rigolin</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Sundt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2017</year>
            <month>Jun</month>
            <day>20</day>
            <volume>135</volume>
            <issue>25</issue>
            <fpage>e1159</fpage>
            <page-range>e1159-e1195</page-range>
            <pub-id pub-id-type="pmid">28298458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Carabello</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Erwin</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Skubas</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Sorajja</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sundt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>JD</given-names>
              </name>
              <collab>ACC/AHA Task Force Members</collab>
            </person-group>
            <article-title>2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Jun</month>
            <day>10</day>
            <volume>129</volume>
            <issue>23</issue>
            <fpage>2440</fpage>
            <page-range>2440-92</page-range>
            <pub-id pub-id-type="pmid">24589852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mathew</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kanmanthareddy</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Prosthetic Heart Valve</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">30725672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shultz</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Timek</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Heiser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Willekes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hooker</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A propensity matched analysis of outcomes and long term survival in stented versus stentless valves.</article-title>
            <source>J Cardiothorac Surg</source>
            <year>2017</year>
            <month>May</month>
            <day>31</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <pub-id pub-id-type="pmid">28569201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dagenais</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cartier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Voisine</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Desaulniers</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Perron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baillot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raymond</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>M&#x000e9;tras</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mathieu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Which biologic valve should we select for the 45- to 65-year-old age group requiring aortic valve replacement?</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2005</year>
            <month>May</month>
            <volume>129</volume>
            <issue>5</issue>
            <fpage>1041</fpage>
            <page-range>1041-9</page-range>
            <pub-id pub-id-type="pmid">15867778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silver</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Detailed anatomy of the normally functioning aortic valve in hearts of normal and increased weight.</article-title>
            <source>Am J Cardiol</source>
            <year>1985</year>
            <month>Feb</month>
            <day>01</day>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>454</fpage>
            <page-range>454-61</page-range>
            <pub-id pub-id-type="pmid">3155899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsushima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karliova</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miyahara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;fers</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Geometry of cusp and root determines aortic valve function.</article-title>
            <source>Indian J Thorac Cardiovasc Surg</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>36</volume>
            <issue>Suppl 1</issue>
            <fpage>64</fpage>
            <page-range>64-70</page-range>
            <pub-id pub-id-type="pmid">33061186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Thomas</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Makaryus</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <chapter-title>Physiology, Cardiovascular Murmurs</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30247833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Topan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carstina</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Slavcovici</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rancea</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Capalneanu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lupse</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Assesment of the Duke criteria for the diagnosis of infective endocarditis after twenty-years. An analysis of 241 cases.</article-title>
            <source>Clujul Med</source>
            <year>2015</year>
            <volume>88</volume>
            <issue>3</issue>
            <fpage>321</fpage>
            <page-range>321-6</page-range>
            <pub-id pub-id-type="pmid">26609264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baumgartner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bax</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>De Bonis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Holm</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lansac</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rodriguez Mu&#x000f1;oz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosenhek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;gren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tornos Mas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vahanian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walther</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wendler</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Windecker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zamorano</surname>
                <given-names>JL</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2017 ESC/EACTS Guidelines for the management of valvular heart disease.</article-title>
            <source>Eur Heart J</source>
            <year>2017</year>
            <month>Sep</month>
            <day>21</day>
            <volume>38</volume>
            <issue>36</issue>
            <fpage>2739</fpage>
            <page-range>2739-2791</page-range>
            <pub-id pub-id-type="pmid">28886619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Carabello</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Erwin</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Skubas</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Sorajja</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sundt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>JD</given-names>
              </name>
              <collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2014</year>
            <month>Jun</month>
            <day>10</day>
            <volume>63</volume>
            <issue>22</issue>
            <fpage>2438</fpage>
            <page-range>2438-88</page-range>
            <pub-id pub-id-type="pmid">24603192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herrmann</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Stram</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Ross Procedure: How to Do It and How to Teach It.</article-title>
            <source>World J Pediatr Congenit Heart Surg</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>624</fpage>
            <page-range>624-627</page-range>
            <pub-id pub-id-type="pmid">31496411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yokoyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kuno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Toyoda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fujisaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takagi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Itagaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ouzounian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>El-Hamamsy</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fukuhara</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ross Procedure Versus Mechanical Versus Bioprosthetic Aortic Valve Replacement: A Network Meta-Analysis.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2023</year>
            <month>Jan</month>
            <day>03</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>e8066</fpage>
            <pub-id pub-id-type="pmid">36565200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Byrne</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Rezai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Okum</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leacche</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Balaguer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Prabhakaran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bridges</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Surgical management of endocarditis: the society of thoracic surgeons clinical practice guideline.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>91</volume>
            <issue>6</issue>
            <fpage>2012</fpage>
            <page-range>2012-9</page-range>
            <pub-id pub-id-type="pmid">21620012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luciani</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Santini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mazzucco</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Autografts, homografts, and xenografts: overview on stentless aortic valve surgery.</article-title>
            <source>J Cardiovasc Med (Hagerstown)</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-6</page-range>
            <pub-id pub-id-type="pmid">17299289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oury</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Clinical aspects of the Ross procedure: indications and contraindications.</article-title>
            <source>Semin Thorac Cardiovasc Surg</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>328</fpage>
            <page-range>328-35</page-range>
            <pub-id pub-id-type="pmid">8899918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mastrobuoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Kerchove</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Navarra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Astarci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Noirhomme</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Poncelet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jashari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rubay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>El Khoury</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Over 20 years experience with aortic homograft in aortic valve replacement during acute infective endocarditis.</article-title>
            <source>Eur J Cardiothorac Surg</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>1158</fpage>
            <page-range>1158-1164</page-range>
            <pub-id pub-id-type="pmid">27229671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Concha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aranda</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Casares</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Merino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alados</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Ribes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Villalba</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The Ross procedure.</article-title>
            <source>J Card Surg</source>
            <year>2004</year>
            <season>Sep-Oct</season>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>401</fpage>
            <page-range>401-9</page-range>
            <pub-id pub-id-type="pmid">15383050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Brown</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Kanmanthareddy</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Ross Procedure for Aortic Valve Replacement</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">30725934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reser</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Caliskan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tolboom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guidotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maisano</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Median sternotomy.</article-title>
            <source>Multimed Man Cardiothorac Surg</source>
            <year>2015</year>
            <volume>2015</volume>
            <pub-id pub-id-type="pmid">26188337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conklin</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Reardon</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Technical aspects of the Ross procedure.</article-title>
            <source>Tex Heart Inst J</source>
            <year>2001</year>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>186</fpage>
            <page-range>186-9</page-range>
            <pub-id pub-id-type="pmid">11678251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berdajs</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Ross procedure for everyone.</article-title>
            <source>Swiss Med Wkly</source>
            <year>2012</year>
            <volume>142</volume>
            <fpage>w13641</fpage>
            <pub-id pub-id-type="pmid">22826114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Etnel</surname>
                <given-names>JRG</given-names>
              </name>
              <name>
                <surname>Grashuis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Huygens</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pekbay</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Papageorgiou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Helbing</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Roos-Hesselink</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Bogers</surname>
                <given-names>AJJC</given-names>
              </name>
              <name>
                <surname>Mokhles</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Takkenberg</surname>
                <given-names>JJM</given-names>
              </name>
            </person-group>
            <article-title>The Ross Procedure: A Systematic Review, Meta-Analysis, and Microsimulation.</article-title>
            <source>Circ Cardiovasc Qual Outcomes</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>e004748</fpage>
            <pub-id pub-id-type="pmid">30562065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skillington</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Mokhles</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Takkenberg</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Larobina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Keefe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wynne</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tatoulis</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Ross procedure using autologous support of the pulmonary autograft: techniques and late results.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>149</volume>
            <issue>2 Suppl</issue>
            <fpage>S46</fpage>
            <page-range>S46-52</page-range>
            <pub-id pub-id-type="pmid">25439787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wenda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Andreeva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kocher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laufer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Andreas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Donor-specific HLA antibodies after fresh decellularized vs cryopreserved native allograft implantation.</article-title>
            <source>HLA</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>96</volume>
            <issue>5</issue>
            <fpage>580</fpage>
            <page-range>580-588</page-range>
            <pub-id pub-id-type="pmid">32975376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukushima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Pearse</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jalali</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sparks</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Pohlner</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Long-term clinical outcomes after aortic valve replacement using cryopreserved aortic allograft.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>148</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-72.e2</page-range>
            <pub-id pub-id-type="pmid">24021951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andreeva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scherzer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kocher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laufer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Andreas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Aortic Valve Replacement in Adult Patients with Decellularized Homografts: A Single-Center Experience.</article-title>
            <source>J Clin Med</source>
            <year>2023</year>
            <month>Oct</month>
            <day>24</day>
            <volume>12</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">37959179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nappi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nenna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petitti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Spadaccio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gambardella</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lusini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Acar</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome of cryopreserved allograft for aortic valve replacement.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>156</volume>
            <issue>4</issue>
            <fpage>1357</fpage>
            <page-range>1357-1365.e6</page-range>
            <pub-id pub-id-type="pmid">29759737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Helder</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kouchoukos</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Zehr</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dearani</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Maleszewski</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Leduc</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heins</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Schaff</surname>
                <given-names>HV</given-names>
              </name>
            </person-group>
            <article-title>Late durability of decellularized allografts for aortic valve replacement: A&#x000a0;word of caution.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>152</volume>
            <issue>4</issue>
            <fpage>1197</fpage>
            <page-range>1197-9</page-range>
            <pub-id pub-id-type="pmid">27131847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-614.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sibilitz</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Risom</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Thygesen</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Johansen</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Gluud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lindschou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hassager</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>K&#x000f8;ber</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Zwisler</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Cardiac rehabilitation increases physical capacity but not mental health after heart valve surgery: a randomised clinical trial.</article-title>
            <source>Heart</source>
            <year>2016</year>
            <month>Dec</month>
            <day>15</day>
            <volume>102</volume>
            <issue>24</issue>
            <fpage>1995</fpage>
            <page-range>1995-2003</page-range>
            <pub-id pub-id-type="pmid">27492941</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
